### Pharmacological Actions of Coenzyme Q10 (Ubiquinone)
Coenzyme Q10 (CoQ10), also known as ubiquinone, is a fat-soluble, vitamin-like compound naturally produced in the body and found in cellular membranes, particularly mitochondria. It plays a critical role in energy production and acts as an antioxidant. Below is a comprehensive list of its pharmacological actions based on available data from preclinical, clinical, and mechanistic studies. For each action, I've included quantitative values where available (e.g., effects on biomarkers, time to peak plasma levels as a proxy for onset of influence, or duration of effects). Note that "time to onset" is not always precisely defined for supplements like CoQ10, as effects are often cumulative with chronic use rather than acute. Plasma levels peak at 5.8–8 hours post-dose, with steady-state achieved in 1–2 weeks due to its long half-life. Influences are described with supporting values from studies.

1. **Mitochondrial Electron Transport Chain Cofactor (ATP Production/Energy Metabolism)**  
   - **Description/Influence**: CoQ10 shuttles electrons between complexes I/II and III in the mitochondrial respiratory chain, facilitating ATP synthesis from carbohydrates and fats. It prevents adenine nucleotide loss from cardiac cells and supports cellular bioenergetics. This is its primary role, enhancing energy in high-demand tissues (e.g., heart, liver, muscles). Deficiency leads to reduced ATP, contributing to fatigue in conditions like heart failure.  
   - **Quantitative Values**: Increases ATP levels by up to 20–30% in mitochondrial assays; in heart failure patients, 100–300 mg/day supplementation improves ejection fraction by 3–12% over 3–6 months. Time to influence: Cumulative, with noticeable energy improvements in 4–12 weeks of daily use. No acute onset data.

2. **Antioxidant Activity**  
   - **Description/Influence**: In its reduced form (ubiquinol), CoQ10 neutralizes free radicals, inhibits lipid peroxidation in cell membranes and lipoproteins (e.g., LDL), and regenerates antioxidants like α-tocopherol (vitamin E) and ascorbate (vitamin C). It protects mitochondria from oxidative damage, reduces superoxide production, and limits formation of oxidized lipids. This mitigates oxidative stress in conditions like atherosclerosis, obesity, NAFLD, and neurodegenerative diseases.  
   - **Quantitative Values**: Reduces lipid peroxidation by 20–50% in in vitro studies; in humans, 100–200 mg/day decreases oxidative stress markers (e.g., F2-isoprostanes) by 15–25% over 4–8 weeks. Time to influence: Plasma antioxidant effects peak at 6–8 hours post-dose; tissue-level protection builds over 1–2 weeks. Half-life supports sustained activity for 33 hours per dose.

3. **Cardiovascular Protection**  
   - **Description/Influence**: Improves endothelial function, preserves nitric oxide for vasodilation, reduces blood pressure, and enhances cardiac contractility. Beneficial in congestive heart failure (CHF), hypertension, and post-heart surgery recovery by reducing oxidative stress and improving energy in cardiac cells. May lower cholesterol in diabetes-related heart risk.  
   - **Quantitative Values**: In CHF, 100–300 mg/day improves symptoms (NYHA class) by 1 grade and ejection fraction by 5–10% over 3 months; reduces systolic BP by 5–11 mmHg in hypertensives over 8–12 weeks. Time to influence: Blood pressure effects in 4–12 weeks; acute plasma changes in 6 hours.

4. **Anti-Inflammatory Effects**  
   - **Description/Influence**: Reduces inflammatory markers by modulating oxidative stress and mitochondrial function. Linked to benefits in metabolic syndrome (MS), obesity, and NAFLD by decreasing cytokine production and inflammation-driven damage.  
   - **Quantitative Values**: Lowers CRP by 0.5–1.5 mg/L and TNF-α by 10–20% with 100–200 mg/day over 8–12 weeks in MS patients. Time to influence: Inflammatory marker reductions in 4–8 weeks.

5. **Neuroprotective Effects**  
   - **Description/Influence**: Protects neurons from oxidative damage, supports mitochondrial function in brain cells, and may slow progression in Parkinson's disease (PD) or migraines by reducing oxidative stress and improving energy metabolism.  
   - **Quantitative Values**: In PD, 300–1200 mg/day slows functional decline (UPDRS score) by 10–20% over 16 months; for migraines, 100–400 mg/day reduces frequency by 30–50% and severity by 40% over 3 months. Time to influence: Migraine reduction in 4–12 weeks; no acute data for PD.

6. **Glycemic Control in Diabetes**  
   - **Description/Influence**: Improves insulin sensitivity by reducing oxidative stress and enhancing mitochondrial function. May lower blood glucose and HbA1c.  
   - **Quantitative Values**: 100–200 mg/day reduces fasting glucose by 10–20 mg/dL and HbA1c by 0.3–0.5% over 3–6 months. Time to influence: 4–12 weeks.

7. **Cell Growth Stimulation and Apoptosis Inhibition**  
   - **Description/Influence**: Promotes cell proliferation and inhibits programmed cell death, supporting tissue repair (e.g., in muscles, heart).  
   - **Quantitative Values**: In vitro, increases cell viability by 15–30%; limited human data. Time to influence: Cumulative over weeks.

8. **Other Actions**  
   - **Pyrimidine Synthesis**: Mediates dihydroorotate oxidation for nucleotide production.  
   - **Muscle Protection**: Reduces statin-induced myopathy by replenishing depleted CoQ10. 100–600 mg/day alleviates symptoms in 50–75% of cases over 1–3 months.  
   - **Quantitative Values**: Limited; time to influence: 4–8 weeks.

### Half-Life
- Plasma elimination half-life: Approximately 33 hours (range 21–34 hours in studies). This supports once- or twice-daily dosing for sustained effects. Formulations may vary slightly (e.g., some enhanced forms up to 92 hours).

### Bioavailabilities
Oral bioavailability is inherently low due to CoQ10's hydrophobicity, large molecular weight (863 Da), and poor aqueous solubility (0.7 ng/mL). Absorption occurs in the small intestine, improved by fatty meals. Values vary by form and formulation:
- **Standard Ubiquinone (Oxidized Form)**: 3–5% absolute bioavailability; plasma increase correlates with dose up to 200–300 mg (e.g., 100 mg raises levels from 0.9 to 3.25 µg/mL).
- **Ubiquinol (Reduced Form)**: 1.5–2 times higher than ubiquinone in some studies (AUC 2-fold higher), but depends on excipients; appears in blood mostly as ubiquinol regardless of ingested form (~95% circulating as ubiquinol).
- **Enhanced Formulations** (e.g., Solubilized, Liposomal, Nanoemulsion, Soft-Gels with Vitamin C or Oils)**: 2–13 times higher than crystalline ubiquinone (e.g., water-soluble Q10Vital syrup: 2.4-fold; liposomal: up to 5–6-fold AUC increase). Inter-individual variation is high (up to 75% difference). Peak plasma: 6–8 hours; second peak at ~24 hours due to enterohepatic recycling.
- **General**: Dietary intake (3–6 mg/day from meat/fish) has negligible plasma impact; supplements require 100+ mg for meaningful elevation. Steady-state plasma: 0.4–1.91 µmol/L baseline, up to 3–5 µg/mL with supplementation.

### Dosages and Safety
CoQ10 is generally recognized as safe (GRAS) by the FDA for use as a supplement, with low toxicity. It's not FDA-approved for medical treatment but widely used. Dosages vary by purpose; split doses improve absorption for >200 mg/day.

- **Safe Range**: 30–1200 mg/day in adults; well-tolerated up to 3000 mg/day in studies. Observed Safety Level (OSL): 1200 mg/day. Acceptable Daily Intake (ADI): 12 mg/kg/day (720 mg for 60 kg person) based on animal NOAEL.
- **Minimum Effective Dose**: Varies by condition; 50–100 mg/day for general antioxidant support or statin myopathy; 100 mg/day for migraines (reduces frequency).
- **Maximum Without High Risks**: 1200 mg/day; higher may cause mild side effects (e.g., GI upset, insomnia at ≥100 mg/day; liver enzyme elevation at ≥300 mg/day). No serious adverse effects reported up to 1200 mg/day.
- **LD50 (Lethal Dose 50%)**: >4000 mg/kg oral in rats/mice (>20 g/kg in some studies); no human LD50 as toxicity is minimal. NOAEL: 600–1200 mg/kg/day in rats (52-week studies); 600 mg/kg/day in dogs.
- **When It Starts to Become Too Dangerous**: No clear threshold for danger; mild GI effects (nausea, diarrhea) at 100–300 mg/day in <1% of users. Rare effects (dizziness, headache) at higher doses. Avoid in biliary obstruction or with warfarin (potential interaction). Safe in pregnancy/lactation per some data, but consult physician. For children: Unlikely adverse at 100 mg/day (≥10 years), but limited studies.

Consult a healthcare provider for personalized dosing, especially with medications or conditions.